Hospital
UNC Rockingham Health Care, INC.
UNC Rockingham Health Care, INC. was paid $10.35M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99283, emergency room visit (moderate) — 41% of everything it billed.
33Billing provider infoUNC ROCKINGHAM HEALTH CARE, INC.
EDEN, NC 27288
EDEN, NC 27288
33aNPI1326048810assigned 07/26/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.35M
24GClaims289,750
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#49 of 92
Median peer was paid$11.47M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SHADOWENS, KAREN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,483 | $1.10M | |
| 2019 | 53,152 | $1.40M | |
| 2020 | 31,732 | $885K | |
| 2021 | 29,749 | $1.16M | |
| 2022 | 48,119 | $2.00M | |
| 2023 | 42,527 | $2.05M | |
| 2024incomplete | 34,988 | $1.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 41% | 34,077 | 30,545 | $4.29M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 11,490 | 10,299 | $2.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 2,688 | 2,302 | $667K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.4% | 5,528 | 4,342 | $659K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.9% | 2,326 | 2,110 | $301K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 2,693 | 2,459 | $296K |
| J3490 | Unclassified drugs | 2.8% | 56,834 | 22,081 | $290K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 6,215 | 5,597 | $127K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 2,418 | 1,968 | $123K |
| 80053 | Comprehensive metabolic panel | 1.1% | 18,738 | 15,780 | $111K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 22,227 | 18,776 | $109K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,261 | 5,409 | $100K |
93 more codes
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 545 | $75K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 431 | $75K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,148 | $70K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,866 | $68K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,008 | $59K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,812 | $55K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,638 | $53K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,205 | $52K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,246 | $47K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 929 | $34K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,202 | $30K |
| 81001 | <1% | 12,787 | $27K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,417 | $22K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 833 | $22K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 653 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 804 | $21K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 804 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,730 | $16K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 90 | $15K |
| 81025 | <1% | 3,756 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,481 | $13K |
| 87081 | <1% | 2,619 | $13K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 112 | $12K |
| 59025 | Fetal non-stress test | <1% | 302 | $12K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 163 | $12K |
| 83690 | <1% | 3,781 | $11K | |
| 84484 | <1% | 3,062 | $10K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 192 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 634 | $9K |
| 83735 | <1% | 2,360 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 831 | $6K |
| 83880 | <1% | 523 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,724 | $5K |
| 85027 | <1% | 891 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,937 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 316 | $4K |
| 87807 | <1% | 466 | $4K | |
| 86787 | <1% | 217 | $4K | |
| 86762 | <1% | 177 | $3K | |
| 84702 | <1% | 879 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 146 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,034 | $3K |
| 86850 | <1% | 277 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 32 | $3K |
| 81003 | <1% | 2,320 | $3K | |
| 86592 | <1% | 547 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 192 | $3K |
| 86701 | <1% | 212 | $3K | |
| 86803 | <1% | 131 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 96 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 807 | $3K |
| 87040 | <1% | 291 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 196 | $2K |
| 87340 | <1% | 169 | $2K | |
| 99218 | <1% | 249 | $2K | |
| 85610 | <1% | 1,231 | $2K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 557 | $2K |
| 87420 | <1% | 102 | $1K | |
| 86901 | <1% | 448 | $1K | |
| 86900 | <1% | 448 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 26 | $946.17 |
| 82947 | <1% | 175 | $866.05 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 66 | $833.90 |
| 80061 | Lipid panel | <1% | 40 | $754.35 |
| 87186 | <1% | 329 | $679.70 | |
| 87077 | <1% | 359 | $637.74 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 93 | $548.99 |
| 86703 | <1% | 40 | $527.40 | |
| 96376 | <1% | 61 | $525.54 | |
| 83605 | <1% | 275 | $502.42 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 104 | $397.16 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 733 | $376.92 |
| 0225U | <1% | 13 | $258.93 | |
| 84439 | <1% | 18 | $240.31 | |
| 82962 | <1% | 276 | $221.14 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 38 | $134.49 |
| J2704 | Injection, propofol, 10 mg | <1% | 29 | $131.37 |
| 83550 | <1% | 12 | $130.68 | |
| 85730 | <1% | 55 | $109.06 | |
| 83540 | <1% | 12 | $96.96 | |
| 85379 | <1% | 31 | $65.87 | |
| 87210 | <1% | 68 | $58.29 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 119 | $51.41 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 100 | $33.24 |
| 36592 | <1% | 24 | $28.91 | |
| A9270 | Non-covered item or service | <1% | 1,900 | $11.60 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 13 | $1.61 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 15 | $1.61 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 46 | $0.60 |
| 36591 | 0% | 14 | $0.00 | |
| 82805 | 0% | 13 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 87 | $0.00 |
| 82948 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHADOWENS, KAREN (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Caldwell Memorial Hospital, INC. | Lenoir, NC | $28.83M |
| Caldwell Memorial Hospital, INC | Granite Falls, NC | $7.30M |
| Caldwell Memorial Hospital, INC | Lenoir, NC | $5.30M |
| Caldwell Memorial Hospital, INC | Lenoir, NC | $1.65M |
| Caldwell Memorial Hospital, INC. | Lenoir, NC | $1.44M |
| Caldwell Memorial Hospital, INC. | Hudson, NC | $1.34M |
| Caldwell Memorial Hospital, INC | Lenoir, NC | $861K |
| Caldwell Memorial Hospital, INC. | Lenoir, NC | $547K |
| Caldwell Memorial Hospital, INC. | Lenoir, NC | $393K |
| Caldwell Memorial Hospital, INC | Lenoir, NC | $323K |
| Caldwell Memorial Hospital, INC | Lenoir, NC | $289K |
| Highland Health Providers Corp | Lynchburg, OH | $251K |
| Caldwell Memorial Hospital, INC | Lenoir, NC | $229K |
| Caldwell Memorial Hospital INC | Lenoir, NC | $224K |
| Caldwell Memorial Hospital, INC. | Blowing Rock, NC | $202K |
| Caldwell Memorial Hospital, INC. | Lenoir, NC | $177K |
| Caldwell Memorial Hosptial, INC | Lenoir, NC | $168K |
| Caldwell Memorial Hospital, INC. | Hudson, NC | $108K |
| Caldwell Memorial Hospital, INC. | Lenoir, NC | $82K |
| Caldwell Memorial Hospital, INC. | Lenoir, NC | $64K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.